Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Gynecol Oncol. 2022 Oct 20;167(3):404–413. doi: 10.1016/j.ygyno.2022.08.021

Fig. 3.

Fig. 3.

Genetic and epigenetic alterations in exceptional benefit (left) and short-term (right) subgroup patients in the rucaparib arm. BL, baseline; BR, best response; BRCA, BRCA1 or BRCA2; CT, chemotherapy; HRD, homologous recombination deficiency; HRR, homologous recombination repair; LOH, loss of heterozygosity; plt, platinum; PPFI, penultimate platinum-free interval.